Dasatinib (senolytic use)

senolytic

Approved medicine for another condition in 8 of 9 markets tracked; in clinical trials in 1.

Evidence so far is from animal studies.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (4)

T3 Tappy 2024 Impact of serial dasatinib and quercetin injections on pelvic organ prolapse and senescence markers in a mouse model doi:10.18632/aging.206120
T3 Cavalcante 2020 Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice doi:10.18632/aging.102772
T3 Sierra-Ramirez 2020 Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin doi:10.18632/aging.103607
T3 Ogura 2022 Dasatinib plus quercetin attenuates frailty in senescence-accelerated mouse prone 10 mice doi:10.1038/s41598-022-06448-5